Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells
Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.
Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia (ALL).
CAR-modified T cell therapies have generated excitement, as novel treatments for patients with ALL. In updated findings from 39 pediatric patients with relapsed/refractory ALL, the complete remission rate was 92%. In this population, this is a good treatment option, Grupp notes.
Given the high-level of efficacy seen with upfront chemotherapy in pediatric patients, Grupp believes the CAR T cell therapies are best suited for later lines of treatment. However, in adult patients with ALL, approximately half of patients progress on frontline therapy. For this population, CAR T cell therapies could be beneficial in earlier settings. At this point, Grupp remains uncertain whether the novel immunotherapies could ever replace frontline chemotherapy in ALL.
<<<
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025